Ocean Biomedical

Update in progress

OCEA (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ocean Biomedical, Inc. is a biopharmaceutical company developing therapies in oncology, fibrosis, and infectious diseases in the United States. Its oncology programs include OCX-253 and OCX-410 for Chi3l1 and PD-1 targets in lung cancer, and OCX-909 for glioblastoma. Fibrosis programs include OCF-203 for IPF. Infectious disease efforts cover malaria vaccines and antibodies (ODA-570, ODA-611, ODA-579). Based in Providence, RI, founded 2019, and a Poseidon Bio, LLC subsidiary with Elkurt, Inc. licenses.

Company score

Sentiment: -0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.13; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.20; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive